ArticleJCI insight2025
Interim report on engineered NK cell trial in lung cancer refractory to immune checkpoint inhibitors.
Miguel A Villalona-Calero et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
9 papers cite it
this papercites it